Brind.
  1. Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.
  2. Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
  3. The FDA and European Medicines Agency engaged in joint coordination regarding regulatory dossier evaluation.

Hospitals in India, Israel, and the Netherlands are currently experimenting with dose reduction protocols for clinical trials under the purview of the FDA and the European Medicines Agency.

1 report, 1 independent Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Hospitals in India, Israel, and the Netherlands are currently experimenting with dose reduction protocols for clinical trials under the purview of the FDA and the European Medicines Agency.

Who's involved

What this event is mainly about
FDAEuropean Medicines Agency

Keep exploring

Part of

The FDA and European Medicines Agency engaged in joint coordination regarding regulatory dossier evaluation. All 1 developments

Within Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.

The entities involved

Coverage

Newest first; wire copies grouped